Activated monocytes kill malignant brain tumor cellsin vitro
- 1 January 1994
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 20 (1) , 35-45
- https://doi.org/10.1007/bf01057959
Abstract
The purpose of our study was to investigate the susceptibility of human glioblastoma multiforme (GBM) cells to lysis by human peripheral-blood monocytes following activation with biological response modifiers (BRM) and to lysis by various BRMs directly. Cytotoxic effects were determined using a monocyte-/BRM-mediated tumor cytotoxicity assay. Human peripheral-blood monocytes from healthy donors were activatedin vitro by incubation for 24 h with different BRMs such as gamma-and beta-interferon (γ, β-IFN), lipopolysaccharide (LPS), muramyldipeptide (MDP) and tumor necrosis factor-alpha (TNF-α) in varying concentrations and combinations. Seven human GBM cell lines as well as an adenocarcinoma brain metastasis cell line and a malignant melanoma cell line served as target cells. Radiolabeled target cells were cocultivated with activated monocytes or with BRMs directly. Cytotoxicity was calculated after 72 h of cocultivation. High levels of cytotoxicity were mediated by monocytes activated with β-IFN in six out of eight brain tumor cell lines and with TNF-α in five cell lines. The combination of two BRMs, in particular the combination of y-IFN + β-IFN and γ-IFN + TNF-α, was associated with an enhanced monocyte mediated lysis exceeding LPS control, whereas the combination of γ-IFN + MDP was very effective against the metastasis cell line. Monocyte-mediated cytotoxicity against tumor target cells was up to ten fold higher than direct cytotoxicity of soluble BRMs. Our data indicate that BRM-stimulated peripheral-blood monocytes exert cytotoxic properties against human glioblastoma cellsin vitro, which exceed those of BRMs alone up to ten fold. The higher tumoricidal activities observed after stimulation with combined BRMs suggest mutual promoting mechanisms of BRMs acting on the stimulation of lyctic activity in human peripheral blood monocytes.Keywords
This publication has 50 references indexed in Scilit:
- Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillanceJournal of Neurosurgery, 1992
- Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: Growth characteristics, cytolytic activity, and cell phenotypeCancer Immunology, Immunotherapy, 1991
- Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumorsCancer Immunology, Immunotherapy, 1991
- Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered selfBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1988
- Immunology of Transplantation in the Central Nervous SylftemStereotactic and Functional Neurosurgery, 1988
- Ex vivo activation of killer monocytes (AKM) and their application to the treatment of human cancerJournal of Clinical Apheresis, 1988
- The biology of interleukin 1 and comparison to tumor necrosis factorImmunology Letters, 1987
- Secretory products of macrophages.Journal of Clinical Investigation, 1987
- Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modalityBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1986
- Macrophages in experimental and human brain tumorsJournal of Neurosurgery, 1979